Cassava 10K Filing Warns of Anticipated Hold, Paints Dire Picture of Alzheimer's Space

Cassava Sciences has warned that the U.S. Food and Drug Administration might order a clinical hold on its studies for Alzheimer's drug simufilam in 2022 after learning that two of its competitors had received hold orders for similar research efforts.